aspirin intake

Phase 3Small molecule

UUniversity Hospital, Rouen

aspirin intake is one of 21 small molecule programs targeting Colon Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colon CancerRecruiting

Colon CancerPhase 3

Recruiting

Competition

Competitive Landscape

22 competitors in Colon Cancer

#DrugCompanyPhaseTrials

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Approved

11 2

Eloxatin

Teva

Phase 3

7 3

Camptosar

Pfizer

Phase 3

3 4

Adrucil

EElorac, Inc.

Phase 3

6 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

4 6

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 3

3 7

Erbitux

IImclone

Phase 3

3 8

Wellcovorin

EEastern Cooperative Oncology Group

Phase 3

3 9

Acetylsalicylic Acid

Bayer

Phase 3

1 10

Libtayo

Regeneron

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Colon Cancer

NCT02945033

Clinical

Trials by Indication[1]

Colon Cancer1 trial

Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk

Recruiting·UUniversity Hospital, Rouen·Phase 3·NCT02945033·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for aspirin intake. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — aspirin intake compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for aspirin intake. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Rouen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity Hospital, Rouen

aspirin intake

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Colon Cancer1 trial

References

Drug Info

Quick Facts

Related News